ORGS Share Price Performance
US$0.051
-3.78 (-98.67%)
Price US$0.051
Share PriceUS$0.051
Orgenesis Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ORGS Community Narratives
There are no narratives available yet.
Recent ORGS News & Updates
Orgenesis Inc. Key Details
Last Reported Earnings
Sep 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -5.24
- Gross Margin
- -97.66%
- Net Profit Margin
- -3,827.81%
- Debt/Equity Ratio
- -63.2%
Orgenesis Inc. Competitors
Snowflake Analysis
About ORGS
- Founded
- 2008
- Employees
- 146
- CEO
- WebsiteView website
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.9%
- 3 Months: 8.7%
- 1 Year: 18.4%
- Year to Date: 14.8%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 6.4% in that time. More promisingly, the market is up 18% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›